Product
OCA
Aliases
6alpha-ethylchenodeoxycholic acid (6-ECDCA), INT-747, OCA Placebo
3 clinical trials
2 indications
Indication
Primary Biliary CholangitisIndication
Biliary AtresiaClinical trial
A Phase 2, Double-Blind, Randomized, Parallel Group Study Evaluating the Efficacy, Safety, and Tolerability of Obeticholic Acid Administered in Combination With Bezafibrate in Subjects With Primary Biliary Cholangitis Who Had an Inadequate Response or Who Were Unable to Tolerate Ursodeoxycholic AcidStatus: Active (not recruiting), Estimated PCD: 2025-10-01
Clinical trial
A Multicenter, Open-Label, Single- and Multiple-Dose, Dose-Finding Study, With an Optional Open-Label Extension to Assess the Safety, Tolerability, and Pharmacokinetics of Obeticholic Acid in Pediatric Subjects With Biliary AtresiaStatus: Terminated, Estimated PCD: 2023-03-09
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Phase 2/3 Study to Assess the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Obeticholic Acid Compared to Placebo in Pediatric Subjects With Biliary Atresia, Post-hepatoportoenterostomyStatus: Not yet recruiting, Estimated PCD: 2027-12-01